Anzeige
Mehr »
Login
Montag, 20.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Breaking News! 22 Jahre "BlueChip"-Power nun bei NurExone!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3E2F2 | ISIN: US33749P4081 | Ticker-Symbol: 366
NASDAQ
20.05.24
15:30 Uhr
3,000 US-Dollar
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ENTERO THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ENTERO THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur ENTERO THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13:06Entero Therapeutics, Inc.: Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) Conference3
FrFirst Wave BioPharma comes ashore with new name as it prepares for phase 3 trial4
DoFirst Wave BioPharma Rebrands to Entero Therapeutics3
DoFirst Wave BioPharma changes name to Entero Therapeutics3
DoFirst Wave BioPharma, Inc. Changes Name to Entero Therapeutics, Inc.116Rebranding introduced as Company advances toward Phase 3 clinical trial with lead asset - latiglutenase for the treatment of celiac disease New Nasdaq ticker symbol is "ENTO" effective May 17, 2024...
► Artikel lesen
DiFirst Wave BioPharma, Inc. - 10-Q, Quarterly Report2
13.05.First Wave BioPharma, Inc. - 8-K, Current Report1
10.05.First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-Market3
24.04.First Wave BioPharma, Inc.: First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients2
17.04.First Wave BioPharma, Inc.: First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase3
15.04.First Wave BioPharma, Inc.: First Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders Conference1
01.04.First Wave BioPharma reports results for the quarter ended in December - Earnings Summary1
29.03.First Wave BioPharma, Inc. - 10-K, Annual Report3
22.03.First Wave BioPharma, Inc. - 8-K, Current Report1
19.03.First Wave BioPharma expected to post a loss of $4.66 a share - Earnings Preview1
18.03.First Wave BioPharma, Inc.: First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference1
14.03.WIMI, First Wave BioPharma and BMR among mid-day movers14
14.03.Why Is First Wave BioPharma (FWBI) Stock Up Today?1
14.03.First Wave BioPharma acquires ImmunogenX to bolster GI pipeline3
14.03.First Wave BioPharma, Inc. - 8-K, Current Report1
Seite:  Weiter >>
65 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1